Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 1 Lung Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Malignancies 1 Adenocarcinoma 1

Interventions

pembrolizumab 57 Nivolumab 50 Ipilimumab 31 Specimen Handling 23 Magnetic Resonance Spectroscopy 19 Cyclophosphamide 14 Biopsy 11 fludarabine 10 binimetinib 10 Opdualag 10 trametinib 9 relatlimab 9 Radiosurgery 9 CTLA-4 Antigen 9 dabrafenib 8 lifileucel 7 fludarabine phosphate 7 aldesleukin 7 encorafenib 6 Interleukin-2 6 cemiplimab 5 atezolizumab 5 Paclitaxel 5 Blood Specimen Collection 5 X-Rays 4 Taxes 4 Pemetrexed 4 Gemcitabine 4 Cisplatin 4 Carboplatin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × sitravatinib × 90 days × Clear all

NCT05542342 2026-06-01

SITISVEAL

Grupo Español Multidisciplinar de Melanoma

Phase 2 Completed

16 enrolled 14 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡